Telesis Bio, Inc. (TBIO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Todd R. Nelson MBA, Ph.D. | Founder & Director | 924.38k | -- | 1967 |
| Mr. Daniel G. Gibson Ph.D. | Chief Technology Officer | 590.37k | -- | 1977 |
| Mr. Robert H. Cutler | Chief Legal Officer | 568.58k | -- | 1968 |
| Mr. Eric Esser | President, CEO, COO & Director | -- | -- | 1969 |
| Mr. William J. Kullback | Chief Financial Officer | -- | -- | 1960 |
| Ms. Jen Carroll | Vice President of Investor Relations | -- | -- | -- |
| Mr. Decky Goodrich M.B.A. | Senior Vice President of Corporate Development | -- | -- | -- |
| Richard Lepke | Director of Investor Relations | -- | -- | -- |
Telesis Bio, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 137
Description
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Corporate Governance
Recent Events
- Apr 23, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Apr 19, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 09, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing